ABEO vs. ACRS, EQ, QURE, ACRX, LUMO, CVAC, DNTH, NUVB, AUPH, and PLRX
Should you be buying Abeona Therapeutics stock or one of its competitors? The main competitors of Abeona Therapeutics include Aclaris Therapeutics (ACRS), Equillium (EQ), uniQure (QURE), AcelRx Pharmaceuticals (ACRX), Lumos Pharma (LUMO), CureVac (CVAC), Dianthus Therapeutics (DNTH), Nuvation Bio (NUVB), Aurinia Pharmaceuticals (AUPH), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical preparations" industry.
Aclaris Therapeutics (NASDAQ:ACRS) and Abeona Therapeutics (NASDAQ:ABEO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.
Abeona Therapeutics has lower revenue, but higher earnings than Aclaris Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Aclaris Therapeutics, indicating that it is currently the more affordable of the two stocks.
Abeona Therapeutics has a net margin of 0.00% compared to Abeona Therapeutics' net margin of -248.28%. Abeona Therapeutics' return on equity of -61.03% beat Aclaris Therapeutics' return on equity.
Aclaris Therapeutics presently has a consensus price target of $22.25, indicating a potential upside of 1,500.72%. Abeona Therapeutics has a consensus price target of $19.00, indicating a potential upside of 272.55%. Given Abeona Therapeutics' higher possible upside, equities analysts plainly believe Aclaris Therapeutics is more favorable than Abeona Therapeutics.
Aclaris Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Abeona Therapeutics has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.
98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 80.6% of Abeona Therapeutics shares are owned by institutional investors. 6.4% of Aclaris Therapeutics shares are owned by insiders. Comparatively, 5.3% of Abeona Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Aclaris Therapeutics had 15 more articles in the media than Abeona Therapeutics. MarketBeat recorded 18 mentions for Aclaris Therapeutics and 3 mentions for Abeona Therapeutics. Aclaris Therapeutics' average media sentiment score of 1.10 beat Abeona Therapeutics' score of 0.87 indicating that Abeona Therapeutics is being referred to more favorably in the news media.
Abeona Therapeutics received 140 more outperform votes than Aclaris Therapeutics when rated by MarketBeat users. Likewise, 70.44% of users gave Abeona Therapeutics an outperform vote while only 66.73% of users gave Aclaris Therapeutics an outperform vote.
Summary
Aclaris Therapeutics and Abeona Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.
Get Abeona Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Abeona Therapeutics Competitors List
Related Companies and Tools
Free ABEO Stock Alerts